Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

QIAGEN Tests Clinically Verified for the Monitoring of Swine Flu

Published: Monday, May 04, 2009
Last Updated: Friday, May 08, 2009
Bookmark and Share
German Bernhard Nocht Institute and Spanish Reference Laboratory detect infections with the H1N1 strain using QIAGEN’s artus influenza test.

Analyses performed by the German Bernhard Nocht Institute for Tropical Medicine have proven that the influenza A / H1N1 virus can be unequivocally detected using a screening test developed by QIAGEN.

The company’s artus Influenza LC RT PCR Kit was successfully used to screen a female patient who had come down with the disease in Mexico and is currently being treated at the Eppendorf University Hospital in Hamburg, Germany.

The patient is currently one of three confirmed cases of swine flu in Germany. The results are a clinical verification of the reliability of the QIAGEN test demonstrated by the findings of a data analysis published the day before.

QIAGEN’s artus kit is considered to be one of the most widely used assays in influenza screening and serves as standard for the detection of influenza A viruses in numerous laboratories around the world. The test was also used by the Instituto de Salud Carlos III, Centro Nacional de Microbiología in Majadahonda (Spain), to screen for Influenza A infections. The institute has verified several possible infections with the H1N1 strain that occurred during the last few days.

The national reference laboratory advises other institutions in Spain seeking support that the artus influenza Kit provides maximum reliability for the first-line screening for H1N1. Following this recommendation, some Spanish hospitals have began to identify possible infections with H1N1 using the artus kit.

”QIAGEN’s artus influenza test can be performed quickly and the results are faultless. This demonstrates the artus test’s ability to detect infections with the influenza A virus including the currently circulating Mexican H1N1 viruses,” said Dr Stephan Guenther, Head of Virology at the Bernhard Nocht Institute in Hamburg.

Screening tests enable verification of potential infections and thus help to contain the spread of the epidemic. Patients that have tested positive for influenza A can then be treated with one of the commonly available pharmaceuticals such as Tamiflu or Relenza, according to the recommendations given by the corresponding drug manufacturers.

The infection with the H1N1 strain of influenza A in sample material obtained from the patient treated in Hamburg was also successfully detected using the company’s second available screening test, the ResPlex II v.2.0 Multiplex Assay. “The signals obtained during the amplification of the corresponding viral sequence were unequivocal, which shows that this test is reliable as well,” said Dr Thomas Grewing, Senior Director Research & Development at QIAGEN.

Regulatory approval of both products for in-vitro diagnostic applications has not been sought yet by QIAGEN, but applications can be officially submitted on a short-term basis depending on the further proliferation of the disease.

Meanwhile, the U.S. FDA regulatory body has cleared tests developed by the national Centers for Disease Control and Prevention (CDC) that include QIAGEN test components. “The CDC tests use our consumables for the extraction of genetic information from samples. One CDC test also incorporates our enzymes needed for the amplification of viral sequences to make the information visible,” continued Grewing.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

QIAGEN Expands Leadership in Liquid Biopsies
QIAGEN and Tokai Pharmaceuticals to co-develop and commercialize the first regulated CTC-based companion diagnostic to guide treatments in prostate cancer.
Tuesday, March 17, 2015
QIAGEN Collaborates with Allele Frequency Community
QIAGEN providing secure bioinformatics infrastructure and software for research and clinical labs to contribute and gain insights from Allele Frequency Community.
Wednesday, February 25, 2015
QIAGEN, AstraZeneca to Develop Liquid Biopsy-based Companion Diagnostic
The collaboration is to advance EGFR mutation profiling in lung cancer patients.
Monday, July 28, 2014
QIAGEN Licenses Blood Cancer Biomarkers
Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including NGS gene panels, for blood cancers.
Saturday, July 26, 2014
QIAGEN Receives FDA Approval for CMV Assay
Assay offers faster quantification of CMV DNA levels in patient samples.
Friday, June 20, 2014
QIAGEN, Lilly form CDx Collaboration
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.
Friday, May 30, 2014
QIAGEN Integrates Content from BIOBASE
The new content expands the world’s most comprehensive, high-quality and up-to-date literature source for clinical research and diagnosis.
Wednesday, May 21, 2014
QIAGEN Reports Fourth Quarter and Full-Year 2013 Results
Company reports adjusted net sales OF $1.31 billion for 2013 with growth in all regions and customer classes.
Thursday, January 30, 2014
QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Companion Diagnostics
Several lymphoma-related biomarkers, including EZH2 Y641 gene mutations, rights acquired from British Columbia Cancer Agency.
Monday, June 10, 2013
QIAGEN Acquires Ingenuity Systems
Suite of web-based applications powered by a unique expert-curated Knowledge Base eases major bottlenecks to leveraging genomic data in research and clinical diagnostics.
Thursday, May 02, 2013
QIAGEN Achieves Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
U.S. launch of therascreen® KRAS RGQ PCR kit offers enhanced approach to guide treatments for approximately 110,000 patients annually in U.S. with colorectal cancer.
Wednesday, July 11, 2012
QIAGEN Unveils Initiative to Create Next-generation Sequencing Portfolio
Company plans to offer sample-to-result workflows that integrate its sample preparation and assay products with a next-generation benchtop sequencer and new bioinformatics.
Tuesday, June 26, 2012
QIAGEN Receives FDA Clearances for Rotor-Gene Q MDx Instrument and Compatible Influenza A/B Assay
Both products receive 510(k) clearance for in vitro diagnostic use in the U.S..
Tuesday, April 17, 2012
QIAGEN Expands Access to State-of-the-Art HPV Screening in China
Coinciding with International Women’s Day, QIAGEN also joins fifth year of campaign to provide free HPV testing to underprivileged women in China.
Thursday, March 08, 2012
QIAGEN and Genome Diagnostics Expands Partnership to Develop Tests for Applications in Prevention and Personalized Healthcare
Extended HLA testing portfolio includes products to assess tolerance for Lumiracoxib and for the early detection of inflammatory diseases.
Friday, June 18, 2010
Scientific News
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos